Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of vaccine or placebo and were followed for a median of 82 days. The vaccine had mainly mild adverse effects and was immunogenic in 99%, similar to...
Saved in:
| Published in: | The New England journal of medicine Vol. 386; no. 21; pp. 2011 - 2023 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Massachusetts Medical Society
26.05.2022
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of vaccine or placebo and were followed for a median of 82 days. The vaccine had mainly mild adverse effects and was immunogenic in 99%, similar to the results in 18-to-25-year-olds. Vaccine efficacy during a delta-variant period was 88%. |
|---|---|
| AbstractList | AbstractBackgroundVaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown.MethodsPart 1 of this ongoing phase 2–3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled expansion evaluation of the selected dose. In part 2, we randomly assigned children (6 to 11 years of age) in a 3:1 ratio to receive two injections of mRNA-1273 (50 μg each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of the vaccine in children and the noninferiority of the immune response in these children to that in young adults (18 to 25 years of age) in a related phase 3 trial. Secondary objectives included determination of the incidences of confirmed Covid-19 and severe acute respiratory syndrome coronavirus 2 infection, regardless of symptoms. Interim analysis results are reported.ResultsIn part 1 of the trial, 751 children received 50-μg or 100-μg injections of the mRNA-1273 vaccine, and on the basis of safety and immunogenicity results, the 50-μg dose level was selected for part 2. In part 2 of the trial, 4016 children were randomly assigned to receive two injections of mRNA-1273 (50 μg each) or placebo and were followed for a median of 82 days (interquartile range, 14 to 94) after the first injection. This dose level was associated with mainly low-grade, transient adverse events, most commonly injection-site pain, headache, and fatigue. No vaccine-related serious adverse events, multisystem inflammatory syndrome in children, myocarditis, or pericarditis were reported as of the data-cutoff date. One month after the second injection (day 57), the neutralizing antibody titer in children who received mRNA-1273 at a 50-μg level was 1610 (95% confidence interval [CI], 1457 to 1780), as compared with 1300 (95% CI, 1171 to 1443) at the 100-μg level in young adults, with serologic responses in at least 99.0% of the participants in both age groups, findings that met the prespecified noninferiority success criterion. Estimated vaccine efficacy was 88.0% (95% CI, 70.0 to 95.8) against Covid-19 occurring 14 days or more after the first injection, at a time when B.1.617.2 (delta) was the dominant circulating variant.ConclusionsTwo 50-μg doses of the mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age; these responses were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.) Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown. Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled expansion evaluation of the selected dose. In part 2, we randomly assigned children (6 to 11 years of age) in a 3:1 ratio to receive two injections of mRNA-1273 (50 μg each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of the vaccine in children and the noninferiority of the immune response in these children to that in young adults (18 to 25 years of age) in a related phase 3 trial. Secondary objectives included determination of the incidences of confirmed Covid-19 and severe acute respiratory syndrome coronavirus 2 infection, regardless of symptoms. Interim analysis results are reported. In part 1 of the trial, 751 children received 50-μg or 100-μg injections of the mRNA-1273 vaccine, and on the basis of safety and immunogenicity results, the 50-μg dose level was selected for part 2. In part 2 of the trial, 4016 children were randomly assigned to receive two injections of mRNA-1273 (50 μg each) or placebo and were followed for a median of 82 days (interquartile range, 14 to 94) after the first injection. This dose level was associated with mainly low-grade, transient adverse events, most commonly injection-site pain, headache, and fatigue. No vaccine-related serious adverse events, multisystem inflammatory syndrome in children, myocarditis, or pericarditis were reported as of the data-cutoff date. One month after the second injection (day 57), the neutralizing antibody titer in children who received mRNA-1273 at a 50-μg level was 1610 (95% confidence interval [CI], 1457 to 1780), as compared with 1300 (95% CI, 1171 to 1443) at the 100-μg level in young adults, with serologic responses in at least 99.0% of the participants in both age groups, findings that met the prespecified noninferiority success criterion. Estimated vaccine efficacy was 88.0% (95% CI, 70.0 to 95.8) against Covid-19 occurring 14 days or more after the first injection, at a time when B.1.617.2 (delta) was the dominant circulating variant. Two 50-μg doses of the mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age; these responses were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.). Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown.BACKGROUNDVaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown.Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled expansion evaluation of the selected dose. In part 2, we randomly assigned children (6 to 11 years of age) in a 3:1 ratio to receive two injections of mRNA-1273 (50 μg each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of the vaccine in children and the noninferiority of the immune response in these children to that in young adults (18 to 25 years of age) in a related phase 3 trial. Secondary objectives included determination of the incidences of confirmed Covid-19 and severe acute respiratory syndrome coronavirus 2 infection, regardless of symptoms. Interim analysis results are reported.METHODSPart 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled expansion evaluation of the selected dose. In part 2, we randomly assigned children (6 to 11 years of age) in a 3:1 ratio to receive two injections of mRNA-1273 (50 μg each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of the vaccine in children and the noninferiority of the immune response in these children to that in young adults (18 to 25 years of age) in a related phase 3 trial. Secondary objectives included determination of the incidences of confirmed Covid-19 and severe acute respiratory syndrome coronavirus 2 infection, regardless of symptoms. Interim analysis results are reported.In part 1 of the trial, 751 children received 50-μg or 100-μg injections of the mRNA-1273 vaccine, and on the basis of safety and immunogenicity results, the 50-μg dose level was selected for part 2. In part 2 of the trial, 4016 children were randomly assigned to receive two injections of mRNA-1273 (50 μg each) or placebo and were followed for a median of 82 days (interquartile range, 14 to 94) after the first injection. This dose level was associated with mainly low-grade, transient adverse events, most commonly injection-site pain, headache, and fatigue. No vaccine-related serious adverse events, multisystem inflammatory syndrome in children, myocarditis, or pericarditis were reported as of the data-cutoff date. One month after the second injection (day 57), the neutralizing antibody titer in children who received mRNA-1273 at a 50-μg level was 1610 (95% confidence interval [CI], 1457 to 1780), as compared with 1300 (95% CI, 1171 to 1443) at the 100-μg level in young adults, with serologic responses in at least 99.0% of the participants in both age groups, findings that met the prespecified noninferiority success criterion. Estimated vaccine efficacy was 88.0% (95% CI, 70.0 to 95.8) against Covid-19 occurring 14 days or more after the first injection, at a time when B.1.617.2 (delta) was the dominant circulating variant.RESULTSIn part 1 of the trial, 751 children received 50-μg or 100-μg injections of the mRNA-1273 vaccine, and on the basis of safety and immunogenicity results, the 50-μg dose level was selected for part 2. In part 2 of the trial, 4016 children were randomly assigned to receive two injections of mRNA-1273 (50 μg each) or placebo and were followed for a median of 82 days (interquartile range, 14 to 94) after the first injection. This dose level was associated with mainly low-grade, transient adverse events, most commonly injection-site pain, headache, and fatigue. No vaccine-related serious adverse events, multisystem inflammatory syndrome in children, myocarditis, or pericarditis were reported as of the data-cutoff date. One month after the second injection (day 57), the neutralizing antibody titer in children who received mRNA-1273 at a 50-μg level was 1610 (95% confidence interval [CI], 1457 to 1780), as compared with 1300 (95% CI, 1171 to 1443) at the 100-μg level in young adults, with serologic responses in at least 99.0% of the participants in both age groups, findings that met the prespecified noninferiority success criterion. Estimated vaccine efficacy was 88.0% (95% CI, 70.0 to 95.8) against Covid-19 occurring 14 days or more after the first injection, at a time when B.1.617.2 (delta) was the dominant circulating variant.Two 50-μg doses of the mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age; these responses were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.).CONCLUSIONSTwo 50-μg doses of the mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age; these responses were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.). In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of vaccine or placebo and were followed for a median of 82 days. The vaccine had mainly mild adverse effects and was immunogenic in 99%, similar to the results in 18-to-25-year-olds. Vaccine efficacy during a delta-variant period was 88%. |
| Author | Melendez Baez, Ivan McPhee, Roderick Yildirim, Inci Ramirez Schrempp, Daniela Creech, C. Buddy Dunn, Michael Girard, Bethany Campbell, James D. Miller, Jacqueline M. Kirstein, Judith Clifford, Robert A. Berthaud, Vladimir Anderson, Evan Yut, Clifford Das, Rituparna Slobod, Karen Zhao, Xiaoping Atz, Andrew M. Hautzinger, Kelly Blair, Ronald Deng, Weiping Zhou, Honghong Tomassini, Joanne E. Pajon, Rolando Pickrell, Paul Schnyder Ghamloush, Sabine Finkelstein, Daniel Montefiori, David C. |
| Author_xml | – sequence: 1 givenname: C. Buddy surname: Creech fullname: Creech, C. Buddy organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 2 givenname: Evan orcidid: 0000-0002-1576-4420 surname: Anderson fullname: Anderson, Evan organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 3 givenname: Vladimir surname: Berthaud fullname: Berthaud, Vladimir organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 4 givenname: Inci surname: Yildirim fullname: Yildirim, Inci organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 5 givenname: Andrew M. surname: Atz fullname: Atz, Andrew M. organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 6 givenname: Ivan surname: Melendez Baez fullname: Melendez Baez, Ivan organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 7 givenname: Daniel surname: Finkelstein fullname: Finkelstein, Daniel organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 8 givenname: Paul surname: Pickrell fullname: Pickrell, Paul organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 9 givenname: Judith surname: Kirstein fullname: Kirstein, Judith organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 10 givenname: Clifford surname: Yut fullname: Yut, Clifford organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 11 givenname: Ronald surname: Blair fullname: Blair, Ronald organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 12 givenname: Robert A. surname: Clifford fullname: Clifford, Robert A. organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 13 givenname: Michael surname: Dunn fullname: Dunn, Michael organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 14 givenname: James D. surname: Campbell fullname: Campbell, James D. organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 15 givenname: David C. surname: Montefiori fullname: Montefiori, David C. organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 16 givenname: Joanne E. surname: Tomassini fullname: Tomassini, Joanne E. organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 17 givenname: Xiaoping surname: Zhao fullname: Zhao, Xiaoping organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 18 givenname: Weiping surname: Deng fullname: Deng, Weiping organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 19 givenname: Honghong surname: Zhou fullname: Zhou, Honghong organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 20 givenname: Daniela surname: Ramirez Schrempp fullname: Ramirez Schrempp, Daniela organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 21 givenname: Kelly surname: Hautzinger fullname: Hautzinger, Kelly organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 22 givenname: Bethany surname: Girard fullname: Girard, Bethany organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 23 givenname: Karen surname: Slobod fullname: Slobod, Karen organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 24 givenname: Roderick surname: McPhee fullname: McPhee, Roderick organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 25 givenname: Rolando surname: Pajon fullname: Pajon, Rolando organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 26 givenname: Rituparna surname: Das fullname: Das, Rituparna organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 27 givenname: Jacqueline M. surname: Miller fullname: Miller, Jacqueline M. organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) – sequence: 28 givenname: Sabine surname: Schnyder Ghamloush fullname: Schnyder Ghamloush, Sabine organization: From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) — both in Nashville; the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine — both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health — all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) — both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group–North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) — all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) — both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) — both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35544369$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kd1LHDEUxYNYdLV99FUCIvRl2nzP5kVYlm1rsRaKFPoUMpk7mmUm0WRmof99s10tVTAv9yG_czj33CO0H2IAhE4o-UCJVB-vV1-_RcsY4ZzKPTSjkvNKCKL20YwQNq9ErfkhOsp5TcqjQh-gQy6lEFzpGbpcbWw_2dHHgGOHhx_Xi4qymuNl3Pi2ohr_tM75ANgHvLzzfZsgYIXHiCnFv8CmvNUtbuEtetPZPsO7x3mMbj6tbpZfqqvvny-Xi6vKSa7HCoCJmrWSi5rPdWdrC61taEsaa7UjNXXaNaRtSKeEBqpsU3dkzohqHFdzy4_Rxc72fmoGaB2EMdne3Cc_2PTbROvN85_g78xt3Bhd1lJaF4P3jwYpPkyQRzP47KDvbYA4ZcOUYlKwUm5Bz16g6zilULbbUloqJsTW8PT_RP-iPJVcAL4DXIo5J-iM8-PfyktA3xtKzPaU5tkpi6p6oXoyfo0_3_HDkE2A9fAK9wdRPKen |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2023_111436 crossref_primary_10_3390_vaccines13010043 crossref_primary_10_3390_vaccines12121418 crossref_primary_10_1016_j_clim_2024_110424 crossref_primary_10_1016_j_jccase_2023_08_009 crossref_primary_10_1056_NEJMoa2209367 crossref_primary_10_3389_fcimb_2023_1201101 crossref_primary_10_1097_QCO_0000000000000948 crossref_primary_10_3390_vaccines12060605 crossref_primary_10_1007_s00431_022_04643_0 crossref_primary_10_3390_medicina59112027 crossref_primary_10_3389_fimmu_2022_1094727 crossref_primary_10_1007_s40820_025_01665_9 crossref_primary_10_3390_microorganisms11030787 crossref_primary_10_1016_j_semerg_2024_102343 crossref_primary_10_1016_j_ccr_2025_216806 crossref_primary_10_3390_vaccines10101696 crossref_primary_10_1177_17407745231217299 crossref_primary_10_1016_S1473_3099_24_00101_4 crossref_primary_10_1016_j_diagmicrobio_2024_116643 crossref_primary_10_1186_s12879_023_08754_3 crossref_primary_10_53126_MEB41281 crossref_primary_10_1007_s40257_022_00721_z crossref_primary_10_3390_vaccines11020214 crossref_primary_10_1002_jppr_1901 crossref_primary_10_1038_s41467_024_52940_z crossref_primary_10_1001_jamapediatrics_2023_2552 crossref_primary_10_1016_j_jped_2022_11_006 crossref_primary_10_1038_s41390_023_02878_7 crossref_primary_10_3389_fpubh_2023_1113003 crossref_primary_10_1097_INF_0000000000004557 crossref_primary_10_1016_j_jmii_2022_10_003 crossref_primary_10_3390_vaccines11010087 crossref_primary_10_1038_s41467_024_50376_z crossref_primary_10_1080_14760584_2024_2397026 crossref_primary_10_1007_s12519_023_00699_6 crossref_primary_10_3390_vaccines12020130 crossref_primary_10_1017_ash_2024_42 crossref_primary_10_1016_S0140_6736_22_00884_4 crossref_primary_10_3389_fimmu_2022_1030238 crossref_primary_10_1007_s00705_025_06248_y crossref_primary_10_3390_jcm13010087 crossref_primary_10_1016_j_vaccine_2024_126426 crossref_primary_10_1097_pq9_0000000000000704 crossref_primary_10_1093_cid_ciac780 crossref_primary_10_3390_vaccines10111954 crossref_primary_10_1007_s00431_023_05380_8 crossref_primary_10_3390_jcm14186542 crossref_primary_10_3390_vaccines10122039 crossref_primary_10_3390_children9101467 crossref_primary_10_1016_j_apsb_2025_03_033 crossref_primary_10_1186_s13052_023_01513_9 crossref_primary_10_1016_S1473_3099_23_00272_4 crossref_primary_10_3390_vaccines10081224 crossref_primary_10_1016_j_ccr_2025_216718 crossref_primary_10_3390_vaccines11030509 crossref_primary_10_1177_09612033241232576 crossref_primary_10_1038_s41541_025_01096_y crossref_primary_10_35366_118346 crossref_primary_10_1093_infdis_jiaf144 crossref_primary_10_1016_j_jinf_2023_10_006 crossref_primary_10_1126_scitranslmed_abq7378 crossref_primary_10_1186_s12969_023_00848_1 crossref_primary_10_1016_j_ahj_2023_11_006 crossref_primary_10_1007_s12519_022_00680_9 crossref_primary_10_1080_14760584_2023_2209177 crossref_primary_10_1093_cid_ciae420 crossref_primary_10_1186_s12929_022_00853_8 crossref_primary_10_3390_vaccines11101526 crossref_primary_10_1111_bcp_15625 crossref_primary_10_1080_21645515_2022_2126668 crossref_primary_10_3389_fcimb_2024_1493885 crossref_primary_10_3389_fpubh_2024_1338208 crossref_primary_10_1111_imr_13108 crossref_primary_10_1016_j_vaccine_2024_01_047 crossref_primary_10_3390_vaccines10071093 crossref_primary_10_3390_vaccines10101655 crossref_primary_10_3390_vaccines12030278 crossref_primary_10_1016_S1473_3099_24_00157_9 crossref_primary_10_1002_pdi3_8 crossref_primary_10_3389_fimmu_2023_1129118 crossref_primary_10_1080_14760584_2023_2260477 crossref_primary_10_3389_fped_2022_995167 crossref_primary_10_1001_jamapediatrics_2022_6243 crossref_primary_10_1016_j_vaccine_2023_12_022 crossref_primary_10_1016_j_intimp_2024_112022 crossref_primary_10_1016_S2352_4642_23_00078_0 crossref_primary_10_1002_psp4_13237 crossref_primary_10_3390_vaccines11020401 crossref_primary_10_3390_ph16091231 crossref_primary_10_1016_S2352_4642_22_00376_5 crossref_primary_10_4103_apjtm_apjtm_717_24 crossref_primary_10_1097_INF_0000000000003707 crossref_primary_10_1080_14760584_2024_2402955 crossref_primary_10_3389_fped_2023_1160929 crossref_primary_10_1097_JCMA_0000000000000774 crossref_primary_10_1016_j_lanwpc_2023_100684 crossref_primary_10_1093_jpids_piae016 crossref_primary_10_1186_s12887_023_04058_2 crossref_primary_10_1016_S1473_3099_24_00501_2 crossref_primary_10_1111_epi_18102 crossref_primary_10_1016_j_vaccine_2024_126223 crossref_primary_10_3389_fpubh_2024_1429265 crossref_primary_10_1038_s41467_024_45181_7 crossref_primary_10_1542_peds_2022_058167 crossref_primary_10_1002_pbc_29985 crossref_primary_10_1177_11779322251324859 crossref_primary_10_3390_microorganisms11071745 crossref_primary_10_1038_s41392_023_01579_1 crossref_primary_10_1093_nar_gkae1280 |
| Cites_doi | 10.1542/peds.2021-054178 10.1056/NEJMc2031915 10.3389/fped.2021.721257 10.1136/bmj-2021-068848 10.15585/mmwr.mm7036e2 10.1093/cid/ciaa1012 10.15585/mmwr.mm6932e3 10.1056/NEJMoa2116298 10.1101/2021.11.11.21265536 10.1056/NEJMoa2109522 10.1126/science.abm3425 10.15585/mmwr.mm7107e4 10.1101/2022.01.24.22269666 10.15585/mmwr.mm7102e1 10.1016/S2352-4642(22)00022-0 10.1056/NEJMc2119912 10.1056/NEJMoa2113017 10.1542/peds.2021-053418 10.1101/2022.01.05.22268617 10.1056/NEJMc2115597 10.1101/2021.10.07.463592 |
| ContentType | Journal Article |
| Contributor | Walker, Shannon Purser Latting, Misty Ramesh, Mayur Thomas, Evelyn Chakraborty, Barsha Hazlett, Claire Luth, Lori Caserta, Mary T Weiner, Leonard B Ferguson, Lori J Merkovic, Ana Nicholson, Erin G Muniz, Gysella B Clinton, John Levin, Myron Hartman, William Luzuriaga, Katherine Randlemon, Julianne Moodley, Amaran Macoy, Lisa Healy, C Mary Nachman, Sharon Gerber, Jeffrey S Martin, Judith M Nayak, Jennifer Bundy, Kimberly He, Hanna Rostad, Christina A Fluno, Kristen Phillips, Shanda Kadish, Matthew Garner, Fredric B Sullivan, John L Rolsma, Stephanie Hoberman, Alejandro Lawler, Rasheeda Pagano-Therrien, Jesica Olson, Heidi Newland, Jason G Russell, Jennifer Morgan, Melinda Loughran, Megan Etheridge, J Bruce Otto, William R Spector, Stephen A Kirstein, Judith L Tuttle, Nick Garcia, Johanna Pleitez, Jenny Paulsen, Grant C Weslowski, Audra Kendrick, Randi Frenk, Robert Douangboupha, Thipsavanh Smith, Christopher A Kasarjian, Julie Kamidani, Satoshi Berman, Gary Allen, Danielle Jativa, David F Barton, Deina Berlatsky, Sarah Muller, William J Gupta, Anil |
| Contributor_xml | – sequence: 1 givenname: Anil K surname: Gupta fullname: Gupta, Anil K – sequence: 2 givenname: Bhavya surname: Gandhi fullname: Gandhi, Bhavya – sequence: 3 givenname: Shrey surname: Acharya fullname: Acharya, Shrey – sequence: 4 givenname: Suresh surname: Boppana fullname: Boppana, Suresh – sequence: 5 givenname: Swetha surname: Pinninti fullname: Pinninti, Swetha – sequence: 6 givenname: Misty surname: Purser Latting fullname: Purser Latting, Misty – sequence: 7 givenname: Gary surname: Berman fullname: Berman, Gary – sequence: 8 givenname: Krista surname: Sullivan fullname: Sullivan, Krista – sequence: 9 givenname: Amy surname: Roehl fullname: Roehl, Amy – sequence: 10 givenname: Heidi surname: Olson fullname: Olson, Heidi – sequence: 11 givenname: Barbara surname: Rizzardi fullname: Rizzardi, Barbara – sequence: 12 givenname: Vanesa surname: Abad fullname: Abad, Vanesa – sequence: 13 givenname: Lori surname: Luth fullname: Luth, Lori – sequence: 14 givenname: Katherine surname: Luzuriaga fullname: Luzuriaga, Katherine – sequence: 15 givenname: John L surname: Sullivan fullname: Sullivan, John L – sequence: 16 givenname: Jesica surname: Pagano-Therrien fullname: Pagano-Therrien, Jesica – sequence: 17 givenname: Mark surname: Turner fullname: Turner, Mark – sequence: 18 givenname: Nick surname: Tuttle fullname: Tuttle, Nick – sequence: 19 givenname: Audra surname: Weslowski fullname: Weslowski, Audra – sequence: 20 givenname: Leonard B surname: Weiner fullname: Weiner, Leonard B – sequence: 21 givenname: Kristen surname: Fluno fullname: Fluno, Kristen – sequence: 22 givenname: Lori J surname: Ferguson fullname: Ferguson, Lori J – sequence: 23 givenname: C Buddy surname: Creech fullname: Creech, C Buddy – sequence: 24 givenname: Stephanie surname: Rolsma fullname: Rolsma, Stephanie – sequence: 25 givenname: Shannon surname: Walker fullname: Walker, Shannon – sequence: 26 givenname: Shanda surname: Phillips fullname: Phillips, Shanda – sequence: 27 givenname: Sharon surname: Nachman fullname: Nachman, Sharon – sequence: 28 givenname: Barsha surname: Chakraborty fullname: Chakraborty, Barsha – sequence: 29 givenname: Jennifer surname: Russell fullname: Russell, Jennifer – sequence: 30 givenname: Fredric B surname: Garner fullname: Garner, Fredric B – sequence: 31 givenname: Joseph P surname: Balsamo fullname: Balsamo, Joseph P – sequence: 32 givenname: Sarah O surname: Crespo fullname: Crespo, Sarah O – sequence: 33 givenname: Christopher A surname: Smith fullname: Smith, Christopher A – sequence: 34 givenname: Danielle surname: Allen fullname: Allen, Danielle – sequence: 35 givenname: Melinda surname: Morgan fullname: Morgan, Melinda – sequence: 36 givenname: William J surname: Muller fullname: Muller, William J – sequence: 37 givenname: Laura surname: Fearn fullname: Fearn, Laura – sequence: 38 givenname: Sarah surname: Berlatsky fullname: Berlatsky, Sarah – sequence: 39 givenname: Evan J surname: Anderson fullname: Anderson, Evan J – sequence: 40 givenname: Christina A surname: Rostad fullname: Rostad, Christina A – sequence: 41 givenname: Satoshi surname: Kamidani fullname: Kamidani, Satoshi – sequence: 42 givenname: Lisa surname: Macoy fullname: Macoy, Lisa – sequence: 43 givenname: Judith M surname: Martin fullname: Martin, Judith M – sequence: 44 givenname: Alejandro surname: Hoberman fullname: Hoberman, Alejandro – sequence: 45 givenname: Gysella B surname: Muniz fullname: Muniz, Gysella B – sequence: 46 givenname: John surname: Clinton fullname: Clinton, John – sequence: 47 givenname: Evelyn surname: Thomas fullname: Thomas, Evelyn – sequence: 48 givenname: Kimberly surname: Bundy fullname: Bundy, Kimberly – sequence: 49 givenname: Daniel surname: Finkelstein fullname: Finkelstein, Daniel – sequence: 50 givenname: Ana surname: Merkovic fullname: Merkovic, Ana – sequence: 51 givenname: Rupert surname: Vallarta fullname: Vallarta, Rupert – sequence: 52 givenname: Shuchismita surname: Bhatt fullname: Bhatt, Shuchismita – sequence: 53 givenname: David F surname: Jativa fullname: Jativa, David F – sequence: 54 givenname: Marcela surname: Jativa fullname: Jativa, Marcela – sequence: 55 givenname: Johanna surname: Garcia fullname: Garcia, Johanna – sequence: 56 givenname: Michael L surname: Leonardi fullname: Leonardi, Michael L – sequence: 57 givenname: J Bruce surname: Etheridge fullname: Etheridge, J Bruce – sequence: 58 givenname: Sandi surname: Judkins fullname: Judkins, Sandi – sequence: 59 givenname: Myron surname: Levin fullname: Levin, Myron – sequence: 60 givenname: Tori surname: Rutherford fullname: Rutherford, Tori – sequence: 61 givenname: Julianne surname: Randlemon fullname: Randlemon, Julianne – sequence: 62 givenname: Deina surname: Barton fullname: Barton, Deina – sequence: 63 givenname: Clifford W surname: Yut fullname: Yut, Clifford W – sequence: 64 givenname: Thipsavanh surname: Douangboupha fullname: Douangboupha, Thipsavanh – sequence: 65 givenname: Jenny surname: Pleitez fullname: Pleitez, Jenny – sequence: 66 givenname: Walter surname: Dehority fullname: Dehority, Walter – sequence: 67 givenname: Hengameh H surname: Raissy fullname: Raissy, Hengameh H – sequence: 68 givenname: Matthew surname: Kadish fullname: Kadish, Matthew – sequence: 69 givenname: Jeffrey S surname: Gerber fullname: Gerber, Jeffrey S – sequence: 70 givenname: Rasheeda surname: Lawler fullname: Lawler, Rasheeda – sequence: 71 givenname: William R surname: Otto fullname: Otto, William R – sequence: 72 givenname: Jason G surname: Newland fullname: Newland, Jason G – sequence: 73 givenname: David A surname: Hunstad fullname: Hunstad, David A – sequence: 74 givenname: Carol surname: Kao fullname: Kao, Carol – sequence: 75 givenname: Daniel S surname: Hsia fullname: Hsia, Daniel S – sequence: 76 givenname: Amy N surname: Thomassie fullname: Thomassie, Amy N – sequence: 77 givenname: Claire surname: Hazlett fullname: Hazlett, Claire – sequence: 78 givenname: Judith L surname: Kirstein fullname: Kirstein, Judith L – sequence: 79 givenname: Hanna surname: He fullname: He, Hanna – sequence: 80 givenname: Julie surname: Kasarjian fullname: Kasarjian, Julie – sequence: 81 givenname: Erin G surname: Nicholson fullname: Nicholson, Erin G – sequence: 82 givenname: C Mary surname: Healy fullname: Healy, C Mary – sequence: 83 givenname: Hana M surname: El Sahly fullname: El Sahly, Hana M – sequence: 84 givenname: Mary T surname: Caserta fullname: Caserta, Mary T – sequence: 85 givenname: Jennifer surname: Nayak fullname: Nayak, Jennifer – sequence: 86 givenname: Grant C surname: Paulsen fullname: Paulsen, Grant C – sequence: 87 givenname: Robert surname: Frenk fullname: Frenk, Robert – sequence: 88 givenname: Jennifer surname: Whitaker fullname: Whitaker, Jennifer – sequence: 89 givenname: William J surname: Towner fullname: Towner, William J – sequence: 90 givenname: Randi surname: Kendrick fullname: Kendrick, Randi – sequence: 91 givenname: Marissa surname: Barron fullname: Barron, Marissa – sequence: 92 givenname: William surname: Hartman fullname: Hartman, William – sequence: 93 givenname: James surname: Conway fullname: Conway, James – sequence: 94 givenname: Sheryl surname: Henderson fullname: Henderson, Sheryl – sequence: 95 givenname: Marcos surname: Zervos fullname: Zervos, Marcos – sequence: 96 givenname: Mayur surname: Ramesh fullname: Ramesh, Mayur – sequence: 97 givenname: Charles surname: Barone fullname: Barone, Charles – sequence: 98 givenname: Stephen A surname: Spector fullname: Spector, Stephen A – sequence: 99 givenname: Amaran surname: Moodley fullname: Moodley, Amaran – sequence: 100 givenname: Megan surname: Loughran fullname: Loughran, Megan |
| Copyright | Copyright © 2022 Massachusetts Medical Society. All rights reserved. Copyright © 2022 Massachusetts Medical Society. Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society |
| Copyright_xml | – notice: Copyright © 2022 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2022 Massachusetts Medical Society. – notice: Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society |
| CorporateAuthor | KidCOVE Study Group |
| CorporateAuthor_xml | – name: KidCOVE Study Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1056/NEJMoa2203315 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary Proquest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1533-4406 |
| EndPage | 2023 |
| ExternalDocumentID | PMC9127699 35544369 10_1056_NEJMoa2203315 NJ202205263862108 |
| Genre | Original Article Clinical Trial, Phase III Clinical Trial, Phase II Randomized Controlled Trial Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | National Institute of Allergy and Infectious Diseases Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: UM1 AI148689 – fundername: NCATS NIH HHS grantid: UL1 TR001453 – fundername: NIAID NIH HHS grantid: UM1 AI148576 – fundername: NIAID NIH HHS grantid: UM1 AI148372 – fundername: NIAID NIH HHS grantid: UM1 AI148684 – fundername: NIAID NIH HHS grantid: UM1 AI148452 – fundername: NIAID NIH HHS grantid: UM1 AI148450 – fundername: NIAID NIH HHS grantid: UM1 AI148575 – fundername: NIA NIH HHS grantid: K76 AG064548 – fundername: ; grantid: contract no. 75A50120C00034 – fundername: ; grantid: UM1AI148372; UM1AI148450; UM1AI148452; UM1AI148575; UM1AI148576; UM1AI148689 |
| GroupedDBID | - 0R 0WA 123 18M 1VV 2KS 2WC 34G 36B 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8C1 9M8 AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABWJO ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACPVT ACRZS ADBBV ADCBC ADFRT ADZYG AENEX AETEA AFFNX AFHKK AFOSN AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BES BHPHI BLC C45 CJ0 CO CS3 DCD DU5 DZ EBS ET EX3 F5P FD8 FM. GJ HCIFZ HF HZ I4R IH2 K-O KM KOO L7B M0R M0T M1P M2M M2O M2P M7P MQT MVM N9A NEJ O9- OK1 OMK OVD P-O P-S P2P RHI RWL RXW S10 S6N SJN TAE TAF TEORI TN5 TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNH YNT YRY YZZ ZA5 ZCA ZHY ZR0 ZVN --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 29N 8AO 8FE 8FH 8FI AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ABUWG ACPFK ADUKH AERZD AFFHD AFKRA AGHSJ AN0 AQUVI BCU BKEYQ BKNYI BNQBC BPHCQ BVXVI BYPQX CCPQU CITATION DWQXO FYUFA GNUQQ GUQSH HF~ HMCUK HZ~ LK8 N4W NAPCQ PCD PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PSYQQ SJFOW TUQ UKHRP YFH YR2 YR5 YYP ~KM CGR CUY CVF ECM EIF NPM PUEGO 7XB BEC K0Y MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c539t-ee2472d5347389fa7aedab1d0baa9c071c9cb0db0f649e16ab7f08206bc368a3 |
| IEDL.DBID | M2P |
| ISICitedReferencesCount | 133 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000795830100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Tue Nov 04 01:39:28 EST 2025 Wed Oct 01 13:56:10 EDT 2025 Tue Oct 07 06:23:31 EDT 2025 Sun Sep 28 01:41:56 EDT 2025 Tue Nov 18 20:47:31 EST 2025 Mon Nov 10 02:41:34 EST 2025 Mon May 30 02:05:41 EDT 2022 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 21 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2022 Massachusetts Medical Society. This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the Covid-19 pandemic or until revoked in writing. Upon expiration of these permissions, PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-ee2472d5347389fa7aedab1d0baa9c071c9cb0db0f649e16ab7f08206bc368a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 A list of the KidCOVE Study Group members is provided in the Supplementary Appendix, available at NEJM.org. |
| ORCID | 0000-0002-1576-4420 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9127699 |
| PMID | 35544369 |
| PQID | 2669562449 |
| PQPubID | 40644 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9127699 proquest_miscellaneous_2662542105 proquest_journals_2669562449 pubmed_primary_35544369 crossref_citationtrail_10_1056_NEJMoa2203315 crossref_primary_10_1056_NEJMoa2203315 mms_nejm_10_1056_NEJMoa2203315 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-05-26 |
| PublicationDateYYYYMMDD | 2022-05-26 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2022 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Gilbert, PB, Montefiori, DC, McDermott, AB (r17) 2022; 375 Delahoy, MJ, Ujamaa, D, Whitaker, M (r5) 2021; 70 (r9) 2021 (r15) 2022 Woodruff, RC, Campbell, AP, Taylor, CA (r6) 2022; 149 Chu, VT, Yousaf, AR, Chang, K (r24) 2021; 385 Girard, B, Tomassini, JE, Deng, W (r21) 2022 Ali, K, Berman, G, Zhou, H (r2) 2021; 385 Walter, EB, Talaat, KR, Sabharwal, C (r13) 2021; 386 (r3) 2022 Kim, L, Garg, S, O’Halloran, A (r4) 2021; 72 Dembiński, Ł, Vieira Martins, M, Huss, G (r8) 2021; 9 Kim, L, Whitaker, M, O’Halloran, A (r7) 2020; 69 (r14) 2022 (r16) 2022 Bruxvoort, KJ, Sy, LS, Qian, L (r18) 2021; 375 Marks, KJ, Whitaker, M, Anglin, O (r11) 2022; 71 Zambrano, LD, Newhams, MM, Olson, SM (r12) 2022; 71 Pajon, R, Doria-Rose, NA, Shen, X (r19) 2022; 386 Burns, MD, Bartsch, YC, Boribong, BP (r23) 2022 Straus, W, Urdaneta, V, Esposito, DB (r26) 2021 Bartsch, YC, St Denis, KJ, Kaplonek, P (r22) 2021 Stephenson, T, Pinto Pereira, SM, Shafran, R (r10) 2022; 6 McLean, HQ, Grijalva, CG, Hanson, KE (r25) 2021 El Sahly, HM, Baden, LR, Essink, B (r1) 2021; 385 Baden, LR, El Sahly, HM, Essink, B (r20) 2021; 385 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_25_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_2_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_16_2 e_1_3_5_15_2 e_1_3_5_14_2 e_1_3_5_12_2 e_1_3_5_13_2 e_1_3_5_10_2 e_1_3_5_11_2 e_1_3_5_18_2 Bruxvoort KJ (e_1_3_5_19_2) 2021; 375 |
| References_xml | – volume: 72 start-page: e206 issue: 9 year: 2021 end-page: e214 ident: r4 article-title: Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization Surveillance Network (COVID-NET). publication-title: Clin Infect Dis – volume: 385 start-page: 2485 year: 2021 end-page: 2487 ident: r20 article-title: Phase 3 trial of mRNA-1273 during the Delta-variant surge. publication-title: N Engl J Med – volume: 385 start-page: 2241 year: 2021 end-page: 2251 ident: r2 article-title: Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. publication-title: N Engl J Med – volume: 69 start-page: 1081 year: 2020 end-page: 1088 ident: r7 article-title: Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 — COVID-NET, 14 states, March 1–July 25, 2020. publication-title: MMWR Morb Mortal Wkly Rep – volume: 70 start-page: 1255 year: 2021 end-page: 1260 ident: r5 article-title: Hospitalizations associated with COVID-19 among children and adolescents — COVID-NET, 14 states, March 1, 2020–August 14, 2021. publication-title: MMWR Morb Mortal Wkly Rep – year: 2021 ident: r22 article-title: Comprehensive antibody profiling of mRNA vaccination in children ;(https://www.biorxiv.org/content/10.1101/2021.10.07.463592v1) publication-title: preprint – volume: 9 start-page: 721257 year: 2021 end-page: 721257 ident: r8 article-title: SARS-CoV-2 Vaccination in children and adolescents — a joint statement of the European Academy of Paediatrics and the European Confederation for Primary Care Paediatricians. publication-title: Front Pediatr – year: 2022 ident: r21 article-title: mRNA-1273 vaccine-elicited neutralization of SARS-CoV-2 Omicron in adolescents and children ;(https://www.medrxiv.org/content/10.1101/2022.01.24.22269666v1) publication-title: preprint – volume: 385 start-page: 1774 year: 2021 end-page: 1785 ident: r1 article-title: Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. publication-title: N Engl J Med – year: 2022 ident: r15 article-title: Health Canada authorizes use of the Moderna Spikevax (50 mcg) COVID-19 vaccine in children 6 to 11 years of age ;(https://www.canada.ca/en/health-canada/news/2022/03/health-canada-authorizes-use-of-the-moderna-spikevax-50-mcg-covid-19-vaccine-in-children-6-to-11-years-of-age.html) – volume: 386 start-page: 1088 year: 2022 end-page: 1091 ident: r19 article-title: SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. publication-title: N Engl J Med – volume: 375 start-page: e068848 year: 2021 end-page: e068848 ident: r18 article-title: Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. publication-title: BMJ – year: 2022 ident: r16 article-title: EMA recommends approval of Spikevax for children aged 6 to 11 ;(https://www.ema.europa.eu/en/news/ema-recommends-approval-spikevax-children-aged-6-11) – volume: 375 start-page: 43 year: 2022 end-page: 50 ident: r17 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. publication-title: Science – volume: 71 start-page: 271 year: 2022 end-page: 278 ident: r11 article-title: Hospitalizations of children and adolescents with laboratory-confirmed COVID-19 — COVID-NET, 14 states, July 2021–January 2022. publication-title: MMWR Morb Mortal Wkly Rep – year: 2021 ident: r25 article-title: Household transmission and clinical features of SARS-CoV-2 infections by age in 2 US communities ;(https://www.medrxiv.org/content/10.1101/2021.08.16.21262121v2) publication-title: preprint – year: 2021 ident: r26 article-title: Myocarditis after mRNA-1273 vaccination: a population-based analysis of 151 million vaccine recipients worldwide ;(https://www.medrxiv.org/content/10.1101/2021.11.11.21265536v1) publication-title: preprint – year: 2022 ident: r23 article-title: Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children ;(https://www.medrxiv.org/content/10.1101/2022.01.05.22268617v1) publication-title: preprint – year: 2022 ident: r14 article-title: ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years ;(https://www.health.gov.au/news/atagi-recommendations-on-the-use-of-spikevax-moderna-covid-19-vaccine-in-children-aged-6-to-11-years) publication-title: Australian Government Department of Health – volume: 386 start-page: 35 year: 2021 end-page: 46 ident: r13 article-title: Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. publication-title: N Engl J Med – volume: 385 start-page: 954 year: 2021 end-page: 956 ident: r24 article-title: Household transmission of SARS-CoV-2 from children and adolescents. publication-title: N Engl J Med – volume: 71 start-page: 52 year: 2022 end-page: 58 ident: r12 article-title: Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years — United States, July–December 2021. publication-title: MMWR Morb Mortal Wkly Rep – volume: 149 start-page: e2021053418 issue: 1 year: 2022 end-page: e2021053418 ident: r6 article-title: Risk factors for severe covid-19 in children. publication-title: Pediatrics – year: 2022 ident: r3 article-title: Coronavirus (COVID-19) update: FDA takes key action by approving second covid-19 vaccine ;(https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine) – year: 2021 ident: r9 article-title: Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States ;(https://stacks.cdc.gov/view/cdc/106439#) publication-title: Centers for Disease Control and Prevention – volume: 6 start-page: 230 year: 2022 end-page: 239 ident: r10 article-title: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. publication-title: Lancet Child Adolesc Health – ident: e_1_3_5_26_2 doi: 10.1542/peds.2021-054178 – ident: e_1_3_5_25_2 doi: 10.1056/NEJMc2031915 – ident: e_1_3_5_9_2 doi: 10.3389/fped.2021.721257 – volume: 375 start-page: e068848 year: 2021 ident: e_1_3_5_19_2 article-title: Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. publication-title: BMJ doi: 10.1136/bmj-2021-068848 – ident: e_1_3_5_6_2 doi: 10.15585/mmwr.mm7036e2 – ident: e_1_3_5_5_2 doi: 10.1093/cid/ciaa1012 – ident: e_1_3_5_4_2 – ident: e_1_3_5_8_2 doi: 10.15585/mmwr.mm6932e3 – ident: e_1_3_5_14_2 doi: 10.1056/NEJMoa2116298 – ident: e_1_3_5_17_2 – ident: e_1_3_5_16_2 – ident: e_1_3_5_27_2 doi: 10.1101/2021.11.11.21265536 – ident: e_1_3_5_10_2 – ident: e_1_3_5_3_2 doi: 10.1056/NEJMoa2109522 – ident: e_1_3_5_18_2 doi: 10.1126/science.abm3425 – ident: e_1_3_5_12_2 doi: 10.15585/mmwr.mm7107e4 – ident: e_1_3_5_22_2 doi: 10.1101/2022.01.24.22269666 – ident: e_1_3_5_13_2 doi: 10.15585/mmwr.mm7102e1 – ident: e_1_3_5_11_2 doi: 10.1016/S2352-4642(22)00022-0 – ident: e_1_3_5_20_2 doi: 10.1056/NEJMc2119912 – ident: e_1_3_5_2_2 doi: 10.1056/NEJMoa2113017 – ident: e_1_3_5_7_2 doi: 10.1542/peds.2021-053418 – ident: e_1_3_5_24_2 doi: 10.1101/2022.01.05.22268617 – ident: e_1_3_5_15_2 – ident: e_1_3_5_21_2 doi: 10.1056/NEJMc2115597 – ident: e_1_3_5_23_2 doi: 10.1101/2021.10.07.463592 |
| SSID | ssj0000149 |
| Score | 2.679525 |
| Snippet | In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of... Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the... AbstractBackgroundVaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and... |
| SourceID | pubmedcentral proquest pubmed crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2011 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 - adverse effects 2019-nCoV Vaccine mRNA-1273 - immunology 2019-nCoV Vaccine mRNA-1273 - therapeutic use Adolescent Adolescent Medicine Adult Adverse events Age Age groups Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Child Childhood Diseases Children Coronavirus Coronaviruses COVID-19 - blood COVID-19 - complications COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects COVID-19 Vaccines - therapeutic use Double-Blind Method FDA approval Heart diseases Humans Immune response Immunization Immunogenicity Infections Infectious Disease Infectious diseases Inflammation Injection Injections mRNA Multisystem inflammatory syndrome in children Myocarditis Original Pediatrics Pericarditis Placebos Population Public health Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Systemic Inflammatory Response Syndrome Teenagers Vaccination Vaccine Efficacy Vaccines Viral Infections Young Adult Young adults |
| SubjectTermsDisplay | Adolescent Medicine Childhood Diseases Coronavirus Immunization Infectious Disease Pediatrics Vaccines Viral Infections |
| SummonAdditionalLinks | – databaseName: New England Journal of Medicine Current dbid: DCD link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZSwMxEA5eiC_eR7VKBPHJ4G6yVx5LVfTBIiKiT0uSzWrF7kpb_f3ObNOl9UB8zmQJc5BvMjvfEHIEKELhSGNmRShYEOSSqUyHTPEcXIBzJWVeDZuIO53k4UHezJDTcS9MYV96VQEfIxpfoMfT4U9xNnypOPeEwKbyefQ1dOOz9tkEX5TDu-7JyJFqfts-dQnN9nqDn_Dl198kJ-6di5V_n3iVLDuISVsjn1gjM7ZYJ4vXroi-Qa7Oa4ZvWua0d9tpMR_wBW1jUx7zJb1XBkVpt6Bt1-xNIzosqe_TRwiNAe5rPdlNcndxfte-ZG6iAjOhkENmLQ9inoUiiAGo5CpWNlPazzytlDSANow02su0l0eBtGBGHeeIESJtRJQosUXmirKwO4RyYzQ3geIJZmSg9gRyS5kpqxO48VXcICdjDafGsY3j0IvXtKp6h1E6pZ0GOa7F30Y0G78JHoC5UlT6bwLNsSVTF46DFFAI5IGAZGSDHNbLEEhYHVGFLd8rGUiWIQOGT2yPDF8fBUFZICLYHU-5RC2AJN3TK0X3uSLrlmDASMrdv869R5Y4dlZ4-NNhk8wN--92nyyYj2F30D-o3PwTBdHzcg priority: 102 providerName: Massachusetts Medical Society |
| Title | Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa2203315 https://www.ncbi.nlm.nih.gov/pubmed/35544369 https://www.proquest.com/docview/2669562449 https://www.proquest.com/docview/2662542105 https://pubmed.ncbi.nlm.nih.gov/PMC9127699 |
| Volume | 386 |
| WOSCitedRecordID | wos000795830100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfohhAS4mMMKIzKSIgnrCXOh-MnVLJO8NASVdVUniLHcaCIJmPp-Pu5c9zQIsYLLz8p8jlKdLbvd2f7jpDXwCIUljRmJogCFoaVZKosIqZ4BUOAcyVlZYtNiNksWS5l5gJurTtWuV0T7UJdNhpj5KdgSIDKgzGS7y5_MKwahburroTGgBwCs_HxSNeUZzvpoxz9dREkl2MTbP4pVppvFOdeEGBF3B2bNFiv27_RzT9PTe6YofMH__sDD8l9R0DpuBsxj8gtUx-RO1O3xX5E7nWBPNrdT3pMPk76fOC0qeh6PhszH9gITfEKH_MlvVAau9JVTVN3NZzGdNNQ36efYSK12G_8xRyTxflkkX5grv4C01EgN8wYHgpeRkEogNZUSihTqsIvvUIpqYGbaKkLryy8Kg6lAaUXokJGERc6iBMVPCEHdVObZ4RyrQuuQ8UT9N9AKwl4orJUpkiAHygxJG-3Csi1y02OJTK-53aPPIrzPX0NyZte_LJLynGT4Ai0mdfm2_omgZOtsnI3edv8t6aG5FXfDNMO91JUbZprKwOuNfjL8Iqn3bjoPwUpXBjE0FvsjZheAFN677fUq682tbcEBcZSPv_3Z70gdznewvDwgOIJOdhcXZuX5Lb-uVm1VyMyEPMLxKWwmAAmqT8ih-8ns2wOT2fpGeDUm1tcIPKpxU8WM0SR_QKO4xQW |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BVEkxKNQWCjFSNBTrSaO8_ABodXSqqu2qwqtUHuKHMcpi7pJabYgfhT_kZm82EWUWw-cM7bs-PPMZ3seAG-QRWgqacyt53tcykxxnSY-1yJDCAihlcqqYhPhaBSdnKjjJfjZxsKQW2WrEytFnRaG7sh30JAglUdjpN5ffOVUNYpeV9sSGjUsDuyP73hkK98NP-D6vhVib3c82OdNVQFufE_NuLVChiL1PRmisc50qG2qEzd1Eq2VQYtrlEmcNHGyQCqLU0nCjOxkkBgviLSH3S7DLUmJxchTUBzPZatq2HZzYdWk9ESKsUOF7QsthON5VIB3zgQuT6fl39jtn06ac1Zv78F_9r8ewv2GXrN-vR8ewZLN1-DOUeNAsAb36mtKVkdfPYbhbpftnBUZm34c9bmLXIsNKECRu4p90oaasknOBk3gOwvYrGCuy05xfiW165_ZJzC-iXmtw0pe5PYZMGFMIozUIqLTKYIgwnO2SrVNImQ_OuzBdrvesWkyr1MBkPO48gDwg3gBHj3Y6sQv6pQj1wluInji3H6ZXiew0WIjblRTGf8GRg9ed59RqdBLkc5tcVXJCF8K7LEHT2sYdkMhgiq9AFuHCwDtBChh-eKXfPK5SlyucAEDpZ7_e1ivYHV_fHQYHw5HBy_grqB4E4dcMTdgZXZ5ZV_CbfNtNikvN6vtxyC-Yfj-AgMtZ1U |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BVVIVYHy6JZSjAScam3iPH1AaLXtilXpqqoqVE6R4ziwiE1KswXx0_h3zCRO2EWUWw-cM7bs-PPMZ3seAC-QRSgqacyNF3jc93PJVZYGXIkcISCEkjKvi01Ek0l8fi5PVuBnGwtDbpWtTqwVdVZquiPvoyFBKo_GSPZz6xZxcjB6c_GVUwUpemlty2k0EDkyP77j8a16PT7AtX4pxOjwbPiW2woDXAeenHNjhB-JLPD8CA13riJlMpW6mZMqJTVaXy116mSpk4e-NDitNMrJZoap9sJYedjtKtyK_EBQ2v5j53Qhc5Vl3vbyyqb3RLrRpyL3pRLC8TwqxrtgDldns-pvTPdPh80FCzi6-x__u3uwaWk3GzT75D6smGIL1o-tY8EWbDTXl6yJynoA48MuCzorczY7nQy4ixyMDSlwkbuSvVeamrJpwYY2IJ6FbF4y12UfcH4VtRt8NA_h7Cbm9QjWirIw28CE1qnQvhIxnVoREDGev2WmTBojK1JRD_bbtU-0zchOhUG-JLVnQBAmS1DpwatO_KJJRXKd4B4CKSnM59l1ArstThKrsqrkN0h68Lz7jMqGXpBUYcqrWkYEvsAee_C4gWQ3FCKuvhdi62gJrJ0AJTJf_lJMP9UJzSUuYCjlzr-H9QzWEbXJu_Hk6AncERSG4pCH5i6szS-vzFO4rb_Np9XlXr0TGSQ3jN5fmMpwGA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+mRNA-1273+Covid-19+Vaccine+in+Children+6+to+11+Years+of+Age&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Creech%2C+C+Buddy&rft.au=Anderson%2C+Evan&rft.au=Berthaud%2C+Vladimir&rft.au=Yildirim%2C+Inci&rft.date=2022-05-26&rft.issn=1533-4406&rft.eissn=1533-4406&rft.volume=386&rft.issue=21&rft.spage=2011&rft_id=info:doi/10.1056%2FNEJMoa2203315&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |